Alnylam Pharmaceuticals Lowers FY2026 Sales Guidance from $5.300B-$5.800B to $5.275B-$5.725B vs $5.580B Est

Alnylam Pharmaceuticals (NASDAQ: ALNY ) lowers FY2026 sales outlook from $5.300 billion-$5.800 billion to $5.275 billion-$5.725 billion vs $5.580 billion estimate.